RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal
tissue. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of
glioblastoma by blocking blood flow to the tumor. Drugs used in chemotherapy such as
irinotecan hydrochloride work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving radiosurgery together with
bevacizumab and irinotecan hydrochloride may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving radiosurgery together with
bevacizumab and irinotecan hydrochloride works in treating patients with recurrent
glioblastoma.